hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06318338 id: UPCC 14523 id: 854756 type: OTHER domain: Penn IRB briefTitle: Virtual Reality to Promote Relaxation Prior to Simulation overallStatus: RECRUITING date: 2024-03 date: 2025-03 date: 2025-03 date: 2024-03-19 date: 2024-03-19 name: Abramson Cancer Center at Penn Medicine class: OTHER briefSummary: The purpose of this study is to assess the feasibility of a pre-simulation virtual reality (VR) platform designed to promote relaxation for cancer patients planned for radiation therapy (RT). conditions: Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 25 type: ESTIMATED name: Virtual Reality Program measure: Feasibility of a pre-simulation VR platform prior to radiation measure: Patient feedback on pre-simulation VR program measure: Patient situational anxiety prior to and after use of VR program sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Perelman Center for Advanced Medicine status: RECRUITING city: Philadelphia state: Pennsylvania zip: 19104 country: United States name: Ching Lai role: CONTACT phone: 267-250-9244 email: Ching.Lai@pennmedicine.upenn.edu lat: 39.95233 lon: -75.16379 hasResults: False
nctId: NCT06318325 id: ADINEGEV-2021_102 briefTitle: Growth Process and Development of the Musculoskeletal System in Young Gymnasts overallStatus: RECRUITING date: 2024-01-01 date: 2026-03-15 date: 2026-03-15 date: 2024-03-19 date: 2024-04-16 name: University of Haifa class: OTHER name: The Academic college Levinsky-Wingate at the Wingate Institute, Netanya, Israel briefSummary: assessment of the musculoskeletal system will be performed twice a year, for three years of young gymnasts. conditions: Development, Adolescent studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 200 type: ESTIMATED name: examination measure: ultrasound tissue characterized measure: muscle strength test measure: range of motion measure: bone strength measure: Bone Age sex: FEMALE minimumAge: 9 Years maximumAge: 16 Years stdAges: CHILD facility: The Academic college Levinsky-Wingate at the Wingate Institute status: RECRUITING city: Netanya country: Israel lat: 32.33291 lon: 34.85992 hasResults: False
nctId: NCT06318312 id: HYP_MR_2024 briefTitle: Effects of Hypoxia on Cognitive Performance acronym: HYPCOG overallStatus: NOT_YET_RECRUITING date: 2024-03-27 date: 2024-04-12 date: 2024-05-03 date: 2024-03-19 date: 2024-03-19 name: University of Castilla-La Mancha class: OTHER briefSummary: The goal of this clinical trial is to determine the effects of different hypoxia exposures (FiO2 = 11%, 13%, 15%, and 21%) on cognitive performance in healthy adults. The main questions it aims to answer are:
* Which hypoxia exposure causes the greatest detriments in cognitive function? conditions: Hypoxia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: BASIC_SCIENCE masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 30 type: ESTIMATED name: Hypoxia measure: Memory measure: Attention measure: Anticipation measure: Reaction time sex: ALL minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT hasResults: False
nctId: NCT06318299 id: 109227 briefTitle: Effects of Exogenous Ketone Ester Supplementation on 3-hydroxybutyrate Concentrations in Human Cerebrospinal Fluid acronym: KetoBrain overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-12 date: 2024-12 date: 2024-03-19 date: 2024-03-21 name: University of Aarhus class: OTHER name: Aarhus University Hospital briefSummary: It is well established that the brain is capable of consuming ketone bodies, especially during low glucose availability, e.g. fasting. Cerebral metabolism of ketone bodies depends on passage of the blood brain barrier and especially the global blood concentration of ketone bodies.
* If acute 3-OHB ingestion increases plasma brain-derived neurotrophic factor (BDNF) levels conditions: Ketosis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: SINGLE whoMasked: PARTICIPANT count: 24 type: ESTIMATED name: Ketone Ester name: Placebo measure: 3-OHB CSF/blood ratio measure: CSF 3-OHB concentrations, POCT measure: CSF 3-OHB concentrations, Mass Spectrometry measure: CSF glucose concentrations measure: Blood 3-OHB concentrations measure: Plasma 3-OHB concentrations measure: Blood glucose concentrations measure: Plasma BDNF concentrations measure: Blood 3-OHB concentrations measure: Plasma 3-OHB concentrations measure: Blood glucose concentrations measure: Plasma BDNF concentrations sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Aarhus University Hospital city: Aarhus zip: 8200 country: Denmark name: Simon Kjær Simonsen, MD role: CONTACT phone: +45 28769491 email: simkjr@clin.au.dk name: Mads Vandsted Svart, PhD role: CONTACT phone: +45 28118221 email: mvsv@clin.au.dk lat: 56.15674 lon: 10.21076 hasResults: False
nctId: NCT06318286 id: MK3475-IIT-60977 briefTitle: Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma acronym: PENINSULA overallStatus: NOT_YET_RECRUITING date: 2024-03-13 date: 2026-04-30 date: 2026-10-30 date: 2024-03-19 date: 2024-03-19 name: Hyogo Medical University class: OTHER name: Merck Sharp & Dohme LLC briefSummary: In this Phase-II study, the investigators will investigate the efficacy and safety of lenvatinib in combination with pembrolizumab and chemotherapy in patients with malignant pleural mesothelioma. conditions: Malignant Pleural Mesothelioma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This is a single-arm, open-label study to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab and chemotherapy in patients with malignant pleural mesothelioma. Patients 18 years of age or older will be eligible for enrollment if they had histologically confirmed unresectable malignant pleural mesothelioma. primaryPurpose: TREATMENT masking: NONE count: 25 type: ESTIMATED name: Lenvatinib name: Pemetrexed name: Cisplatin/Carboplatin name: Pembrolizumab measure: Tumor shrinkage (response rate) (Physician Judgment by Medical Institution, Modified RECIST [Response Evaluation Criteria in Solid Tumors] criteria) measure: Progression-Free survival (PFS) (Physician Judgment by Medical Institution, Modified RECIST criteria) measure: Overall survival time (OS) measure: Tumor shrinkage (disease control rate) (Physician Judgment by Medical Institution, Modified RECIST criteria) measure: Duration of response (Physician Judgment by Medical Institution, Modified RECIST criteria) measure: Best overall response (Physician Judgment by Medical Institution, Modified RECIST criteria) measure: Incidence of adverse events sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hyogo Medical University Hospital city: Nishinomiya state: Hyogo zip: 6638501 country: Japan name: Kozo Kuribayashi, MD, PhD role: CONTACT phone: +81-798-45-6596 email: kuririn@hyo-med.ac.jp name: Tetsuya Takagawa, MD, PhD role: CONTACT phone: +81- 798-45-6265 email: takagawa@hyo-med.ac.jp name: Nobukazu Fujimoto, MD, PhD role: PRINCIPAL_INVESTIGATOR name: Keisuke Aoe, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 34.71562 lon: 135.33199 hasResults: False
nctId: NCT06318273 id: M24-742 briefTitle: A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer overallStatus: RECRUITING date: 2024-03-08 date: 2027-06-16 date: 2027-06-17 date: 2024-03-19 date: 2024-04-09 name: AbbVie class: INDUSTRY briefSummary: Prostate cancer has the second highest incidence rate and is the fifth leading cause of cancer-related deaths among men worldwide. The purpose of this study is to assess safety, pharmacokinetics, and efficacy of ABBV-969 as a monotherapy.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans. conditions: Metastatic Castration-Resistant Prostate Cancer studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 120 type: ESTIMATED name: ABBV-969 measure: Percentage of Participants With Adverse Events (AEs) measure: Percentage of Participants Achieving Prostate Specific Antigen (PSA) response measure: Maximum Observed Plasma Concentration (Cmax) of ABBV-969 measure: Time to Maximum Observed Concentration (Tmax) of ABBV-969 measure: Terminal Phase Elimination Half-Life (t1/2) of ABBV-969 measure: Area Under the Plasma/Serum Concentration Versus Time Curve (AUC) of ABBV-969 measure: Antidrug Antibody (ADA) measure: Neutralizing Antibodies (nAbs) measure: Recommended Phase 2 Dose (RP2D) of ABBV-969 (Dose-Escalation Phase) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: City of Hope /ID# 262059 status: RECRUITING city: Duarte state: California zip: 91010 country: United States lat: 34.13945 lon: -117.97729 facility: Carolina BioOncology Institute /ID# 261602 status: RECRUITING city: Huntersville state: North Carolina zip: 28078 country: United States lat: 35.41069 lon: -80.84285 facility: NEXT Oncology /ID# 261601 status: RECRUITING city: San Antonio state: Texas zip: 78229 country: United States lat: 29.42412 lon: -98.49363 hasResults: False
nctId: NCT06318260 id: 2023-508298-10-00 briefTitle: Haemodynamic Effects of Dobutamine in Patients With Wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt) acronym: DobATTR overallStatus: RECRUITING date: 2024-04-08 date: 2025-09 date: 2026-03 date: 2024-03-19 date: 2024-04-17 name: Steen Hvitfeldt Poulsen class: OTHER briefSummary: The goal of this clinical trial is to test the effects of the inotropic drug named dobutamine, in patients with wild-type Transthyretin Amyoid Cardiomyopathy (ATTRwt). The main questions it aims to answer are:
Participants will be given increasing dosages of dobutamine infusion, and its effect on cardiac output and filling pressures will be assessed non-invasively by echocardiography, and invasively by right heart catheterization, simultaneously. conditions: ATTR Amyloidosis Wild Type studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Prospective, single-centre, one arm clinical explorative study, with consecutive enrolment. primaryPurpose: TREATMENT masking: NONE count: 35 type: ESTIMATED name: Dobutrex measure: Cardiac output measure: Increase in invasively measured SVI by ≥ 20%. measure: Reduction in mean PAWP and/or mPAP by 10 %. measure: Increase in LVEF and LV-global longitudinal strain (LV-GLS) of absolute 10 %. measure: Correlation between echo- and invasive measured SVI, and CO. measure: Rate of complications (i.e. Systolic blood pressure drop < 90 mmHg, arrhythmias)/symptomatic side effects. sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT facility: Department of Cardiology, Aarhus University Hospital status: RECRUITING city: Aarhus zip: 8200 country: Denmark name: Ali Hussein Jaber Mejren, MD role: CONTACT phone: 0045 91 65 18 48 email: alimej@clin.au.dk lat: 56.15674 lon: 10.21076 hasResults: False
nctId: NCT06318247 id: 2022-134(R) briefTitle: Using Xenograft Combined With Barrier Membrane to Improve the Formation of Deep Periodontal Pockets overallStatus: RECRUITING date: 2023-06-01 date: 2024-12-30 date: 2025-12-30 date: 2024-03-19 date: 2024-03-19 name: The Dental Hospital of Zhejiang University School of Medicine class: OTHER briefSummary: To evaluate the clinical effect of site preservation after third molars extraction by using tooth extraction of third molars with site preservation using bio-oss and bio-guide in preventing the formation of deep periodontal pockets in the distal of second molars. conditions: Periodontal Pocket conditions: Periodontal Bone Loss conditions: Impacted Third Molar Tooth studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 30 type: ESTIMATED name: site preservation measure: Probing pocket depths (PPD) measure: Distal bone wall defect (DBWD) measure: Clinical attachment lose (CAL) measure: Bleeding on probing (BOP) measure: Pain score measure: Patient satisfaction measure: Gingival index (GI) sex: ALL minimumAge: 26 Years maximumAge: 45 Years stdAges: ADULT facility: Stomatology Hospital, Zhejiang University School of Medicine status: RECRUITING city: Hangzhou state: Zhejiang zip: 310000 country: China name: Jue Shi, Doctor role: CONTACT phone: +86 13757171359 email: dentistsj@zju.edu.cn lat: 30.29365 lon: 120.16142 hasResults: False
nctId: NCT06318234 id: 202435 briefTitle: PET/MR Evaluation of Regression Grading After Neoadjuvant Therapy for Rectal Cancer overallStatus: RECRUITING date: 2024-01-01 date: 2025-12-31 date: 2025-12-31 date: 2024-03-19 date: 2024-03-19 name: Xiao Chen class: OTHER briefSummary: This project aims to evaluate the role of 18F-FAPI combined with 18F-FDG PET/MRI imaging in quantitatively and accurately evaluating the grading of rectal cancer after SCRT neoadjuvant therapy in patients with advanced rectal cancer as the research object, with postoperative histopathological analysis as the reference index, and to assess the ability of patients to achieve pCR. A diagnostic model and evaluation system will also be constructed. conditions: Rectal Cancer studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 32 type: ESTIMATED name: 18F-FAPI，18F-FDG measure: Evaluation efficacy of tumor regression level measure: expression of FAP measure: expression of GLUT1 measure: SUV sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Nuclear Medicine, Daping Hospital of Army Medical University status: RECRUITING city: Chongqing country: China name: Xiao Chen, Ph.D role: CONTACT phone: +8615922970174 email: xiaochen229@foxmail.com lat: 29.56278 lon: 106.55278 hasResults: False
nctId: NCT06318221 id: 06156930 briefTitle: Effects of Perioperative Immunonutrition in Patients With Head and Neck Cancer overallStatus: COMPLETED date: 2019-05-01 date: 2021-02-01 date: 2021-02-01 date: 2024-03-19 date: 2024-03-19 name: TC Erciyes University class: OTHER briefSummary: A prospective randomized controlled study compared the effects of perioperative immunonutrition and standard enteral nutrition (EN) on postoperative short-term outcomes of patients with head and neck (HNC).
Five days before surgery and the postoperative day 10, immunonutrition support was given to the intervention group (n=17), and standard EN support was given to the control group (n=17). Body analyses were made, food consumption records were taken, NRS-2002 and quality of life scales were applied, and biochemical parameters were recorded. conditions: Head and Neck Cancer conditions: Nutrition, Healthy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Patients were classified according to tumor location (oral cavity, oropharynx, larynx or hypopharynx) and body weight loss, approximately equally in both groups. Accordingly, patients were randomly assigned (by computer) into either the immunonutrition (intervention group) or standard EN (control group) groups. primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 34 type: ACTUAL name: Experimental (Immunonutrition) Group name: Active Comparator Group ( Standard enteral nutrition) measure: Body weight measure: Body weight loss measure: Body mass index measure: Resting metabolic rate measure: Nutrition Risk Screening 2002 measure: The EORTC Core Quality of Life questionnaire-30 (EORTC QLQ-C30) measure: The EORTC Quality of life - Head and Neck Cancer Module (EORTC QLQ-H & N35) measure: Albumin measure: C-reactive protein measure: Prealbumin measure: Length of hospital stay measure: Complication development status sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Erciyes University city: Talas state: Kayseri zip: 38280 country: Turkey lat: 38.6908 lon: 35.5538 hasResults: False
nctId: NCT06318208 id: C-LCI briefTitle: Pulmonary Function in Non-hospitalized Adults and Children After Mild COVID-19 overallStatus: COMPLETED date: 2021-04-20 date: 2022-01-03 date: 2022-01-03 date: 2024-03-19 date: 2024-03-26 name: University of Rostock class: OTHER briefSummary: The study investigates whether patients with mild SARS-CoV-2 infection, who stayed at home during their infection and weren't hospitalized, have any persisting sequelae in pulmonary function.
Additionally to lung function testing we did a throat swab at each appointment to analyse via Multiplex PCR whether the patients had any other respiratory infection at the time of the pulmonary function testing. conditions: SARS-CoV-2 Infection studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 110 type: ACTUAL name: lung function testing measure: Pulmonary function measure: Changes in pulmonary function measure: Sociodemographic factors sex: ALL minimumAge: 6 Years maximumAge: 60 Years stdAges: CHILD stdAges: ADULT facility: Kinder- und Jugendklinik Universitätsmedizin Rostock city: Rostock zip: 18057 country: Germany lat: 54.0887 lon: 12.14049 hasResults: False
nctId: NCT06318195 id: 2023-06821-01 briefTitle: Condensed Digital Prolonged Exposure for Individuals Treated Within Somatic Trauma Care. acronym: CiPE overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2026-02 date: 2026-08 date: 2024-03-19 date: 2024-03-19 name: Karolinska Institutet class: OTHER name: Karolinska Universitetssjukhuset briefSummary: The purpose of the study is to investigate the feasibility of implementation aspects, treatment effects and change processes regarding a brief trauma-focused Internet-based CBT treatment, for patients who have been treated in trauma care at Karolinska University Hospital and who exhibit symptoms of psychological consequences of the traumatic event. Another aim is to explore factors (predictors, moderators and mediators) that influence the effect of the treatment, in order to better understand who responds to the treatment. conditions: Post Traumatic Stress Disorder conditions: Acute Stress Disorder studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Prolonged exposure will be offered in a brief digital format with therapist support for three weeks. Treatment comprises of psychoeducation, rationales, in vivo exposure, imaginal exposure and relapse prevention. primaryPurpose: TREATMENT masking: NONE count: 250 type: ESTIMATED name: Condensed Internet delivered prolonged exposure (CIPE) measure: Change in PTSD symptoms as assessed by the PTSD Check List - DSM-5 (PCL-5) measure: Change in depressive symptoms as measured by the Patient Health Questionnaire-9 (PHQ-9) measure: Change in psychosocial impairment measured by The Work and Social Adjustment Scale (WSAS), adapted to symptoms of post-traumatic stress. measure: Participants satisfaction with treatment. measure: Adverse events related to treatment. measure: Number of completed treatment modules measure: Number of messages sent and received in the digital platform measure: Number of completed home work assignments by the participant during the treatment period measure: The proportion of participants that conducts the weekly measures and further assessment points measure: The proportion of participants that go through the entire treatment period measure: Number of drop-outs from treatment measure: Rates of inclusion to the study sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Karolinska Universitetssjukhuset; Tema Kvinnohälsa och Hälsoprofessioner; Medicinsk Enhet Medicinsk Psykologi; Sektion Beteendemedicin city: Stockholm country: Sweden name: Charlotte Gentili, PhD role: CONTACT phone: +46760482895 email: charlotte.s.gentili@regionstockholm.se name: Mike Kemani, PhD role: CONTACT email: mike.kemani@regionstockholm.se lat: 59.33258 lon: 18.0649 hasResults: False
nctId: NCT06318182 id: NCT-SBF-EK-001 briefTitle: Testicular Self-Examination Awareness in Young Men overallStatus: ACTIVE_NOT_RECRUITING date: 2022-12-09 date: 2023-11-20 date: 2024-07-15 date: 2024-03-19 date: 2024-03-19 name: Hitit University class: OTHER name: Ondokuz Mayıs University briefSummary: This study aims to determine the effect of education based on the health belief model on testicular self-examination awareness and health beliefs in young men.
H1g Hypothesis: The training based on the health belief model will increase the mean scores of the self-efficacy subscale of young men in the experimental group compared to those in the control group. conditions: Testicular Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 120 type: ACTUAL name: Education measure: Demographic information and testicular cancer questionnaire measure: Testicular Cancer Knowledge Test measure: Health Beliefs Scale for Testicular Cancer and Testicular Self-Examination measure: For the control group, Testicular Cancer Knowledge Test measure: For the control group, Health Beliefs Scale for Testicular Cancer and Testicular Self-Examination measure: Testicular Cancer Knowledge Test measure: Health Beliefs Scale for Testicular Cancer and Testicular Self-Examination sex: MALE minimumAge: 15 Years maximumAge: 35 Years stdAges: CHILD stdAges: ADULT facility: Hitit University city: Corum zip: 19000 country: Turkey lat: 40.54889 lon: 34.95333 hasResults: False